| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.76▲ | 7.68▲ | 7.67▲ | 7.78▲ | 7.94▼ |
| MA10 | 7.74▲ | 7.62▲ | 7.62▲ | 7.82▼ | 8.36▼ |
| MA20 | 7.70▲ | 7.60▲ | 7.62▲ | 7.94▼ | 8.49▼ |
| MA50 | 7.61▲ | 7.70▲ | 7.75▲ | 8.48▼ | 7.49▲ |
| MA100 | 7.60▲ | 7.76▲ | 7.98▼ | 8.55▼ | 7.34▲ |
| MA200 | 7.74▲ | 7.96▼ | 8.14▼ | 7.75▲ | 7.56▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | 0.030▲ | 0.031▲ | -0.010▼ | -0.189▼ |
| RSI | 65.786▲ | 61.294▲ | 55.067▲ | 44.928▼ | 46.749▼ |
| STOCH | 83.778▲ | 85.972▲ | 64.361 | 27.744 | 15.161▼ |
| WILL %R | -11.538▲ | -5.000▲ | -4.545▲ | -73.944 | -83.272▼ |
| CCI | 71.471 | 177.313▲ | 173.249▲ | -78.777 | -124.236▼ |
| MA | $FENC Price Crossed Above MA(200) | Set Alert |
|
Tuesday, December 02, 2025 07:56 AM
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
|
|
Tuesday, December 02, 2025 04:24 AM
Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received ...
|
|
Wednesday, November 26, 2025 03:05 AM
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/12/25 | 7.58 | 7.79 | 7.47 | 7.78 | 94,855 |
| 03/12/25 | 7.60 | 7.705 | 7.3501 | 7.57 | 155,185 |
| 02/12/25 | 7.77 | 7.85 | 7.51 | 7.61 | 135,764 |
| 01/12/25 | 8.17 | 8.235 | 7.70 | 7.73 | 189,964 |
| 28/11/25 | 7.835 | 8.25 | 7.835 | 8.19 | 110,948 |
| 26/11/25 | 7.90 | 8.00 | 7.72 | 7.89 | 248,111 |
| 25/11/25 | 7.70 | 8.205 | 7.54 | 7.95 | 315,514 |
| 24/11/25 | 7.88 | 7.88 | 7.495 | 7.72 | 92,599 |
| 21/11/25 | 7.80 | 8.21 | 7.66 | 7.88 | 264,005 |
| 20/11/25 | 8.34 | 8.34 | 7.75 | 7.84 | 153,210 |
|
|
||||
|
|
||||
|
|